Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
SYNGENE
Mr. Siddharth Mittal BCom, CA, CPA · Bengaluru, India · 6,692 employees
₹414.25
▲+1.25%SYNGENE’s diagnostics arm is stuck in a low‑margin, high‑valuation zone with modest growth, despite a slight uptick in price and institutional backing.
Exchange
NSI
Currency
INR
Day range
₹406.00 – ₹417.50
52-week range
₹380.00 – ₹728.60
Sector
Healthcare
Industry
Diagnostics & Research
AI investment rating
AI analysis70% confidence
The stock is priced near the upper third of its 52‑week range, implying a modest upside if valuation compresses.
43.1% below the 1-year high · trend up
Hedge-fund memo
Today
Price up 1.25% at ₹414.25; still below 52‑week high.
This week
Stable activity, minor swing; volatility remains within day range.
This month
Consistent trading volume around 1.2M; no headline moves.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Neutral
11 headlines · 9 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 2 of 4 recent quarters (EPS actual vs. consensus).
3.7823 vs 2.04
85.41% surprise
1.2978 vs 2.46
-47.24% surprise
1.67 vs 2.16667
-22.92% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| SYNGENE | 166.74B | 52.70 | 6.62% | 20.82% | 1.80% |
| ALKEM | 695.45B | 30.25 | 17.56% | 11.42% | 14.60% |
| LAURUSLABS | 962.46B | 88.05 | — |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Margin erosion due to rising commodity costs
Mitigation: Emphasise cost STARTER initiatives and supply‑chain optimisation.
Regulatory changes impacting diagnostic fee structures
Mitigation: Maintain regulatory monitor and diversify across non‑regulated services.
Business intelligence
Competitive moat
A dispersed network of test sites and established research pipelines give SYNGENE moderate scale and brand leverage ubicación in the Indian diagnostic sector.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
No notable recent activity flagged.
Catalyst calendar
Są Q4 earnings release
Product launch roadmap announcement
Thesis builder
Bull case
If SYNGENE can tighten margins and accelerate testabara trail, the high P/E may compress toward a more average diagnostics peer group.
Base case
Current performance reflects പോകൽ；
Bear case
A continued low growth trajectory distribuir shaft may drive the valuation into a prolonged trough.
Time horizon
12–24 months
Est. CAGR
0.5–2%
Entry (qual.)
Add to portfolio when price dips near the 52‑week low or when earnings beat consensus.
Exit (qual.)
Consider reducing exposure if margin damage or assets clean‑up ensues.
Overall conviction 70%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how SYNGENE fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain SYNGENE for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Accumulate if valuation normalises; otherwise hold steady until clear upside catalysts surface.
marketscreener.com·1d ago·earnings report with no sentiment
BioTecNika·1d ago·freshers hiring shows business growth
TradingView·1d ago·net loss revenue decline forex impact
BioTecNika·1d ago·specialized hiring indicates expansion
hrtoday.in·1d ago·senior CDMO hire strengthens capabilities
Indian Pharma Post·2d ago·key appointment in core business area
BioTecNika·2d ago·ongoing workforce expansion activity
MarketsMojo·2d ago·mixed technical market signals unclear
The Economic Times·5d ago·part of strong stock rally group
equitypandit.com·6d ago·generic weekly outlook no impact
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
2.15 vs 1.59
35.22% surprise
| 25.39% |
| 29.10% |
| IPCALAB | 446.21B | 39.18 | 13.22% | 18.48% | 6.30% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹406.00
Resistance (day/52w high)
₹417.50
Volume
12,19,538
Trend
up
RSI (14)
49
MACD
bullish
MA cross
death
50-day MA
₹436.49
200-day MA
₹504.28
vs 200-DMA
-17.9%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.